9th Annual Sickle Cell Disease Research and Educational Symposium (April 10 – 13, 2015)

Evaluation of purified poloxamer-188 (vepoloxamer) on sickle red blood cell (RBC) adhesion and membrane fragility utilizing microfluidic-based flow adhesion bioassays

International Stroke Conference 2015 (February 11 – 13, 2015)

Combination of Vepoloxamer and tPA extends the therapeutic window of stroke

56th Annual Meeting of the American Society of Hematology (ASH) (December 6 – 9, 2014)

Pro-coagulant Actions of Circulating Microparticles in Sickle Cell Anemia and Sepsis Associated Coagulopathy and their Modulation by a Triblock Polymer MST 188

American Heart Association (AHA) Scientific Sessions 2014 (November 19, 2014)

Short (2 hour) Intravenous Infusion of Vepoloxamer (MST-188) Elicits Prolonged (1-2 weeks) Improvement in Biomarkers in Dogs with Advanced Heart Failure

8th Annual Sickle Cell Disease Research & Educational Symposium (April 11, 2014)

Effect of Purified Poloxamer 188 or Various Dextrans on Erythrocyte Sedimentation Rate in Patients with Sickle Cell Disease

National Institutes of Health Annual Sickle Cell Disease Research Clinical Meeting (August 21, 2013)

EPIC – An Ongoing Pivotal Phase 3 Study in Patients with Sickle Cell Disease

7th Annual Sickle Cell Disease Research & Educational Symposium (April 17, 2013)

Is There a Role for a Rheologic Agent in Transfusion?
Poster presented by R. Martin Emanuele, Ph.D., Senior Vice President, Development

Evaluation of Purified Poloxamer 188 in Children (EPIC) – Key Design Considerations
Poster presented by Santosh J. Vetticaden, Ph.D., M.D., Chief Medical Officer




Click here to view our latest press releases, SEC filings, and information about company events, media, and analyst coverage. read more


Click here to learn more about our lead product candidate, vepoloxamer.
  read more

Clinical Trials

We have initiated a Phase 3 clinical study of vepoloxamer for the treatment of sickle cell disease. Click here for more info. read more